Fertility and Sterility
Volume 91, Issue 4, Supplement , Pages 1332-1335 , April 2009

Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome

  • Enrico Carmina, M.D.

      Affiliations

    • Department of Internal Medicine, University of Palermo, Palermo, Italy
    • ,
  • Salvo Bucchieri, M.D.

      Affiliations

    • Department of Internal Medicine, University of Palermo, Palermo, Italy
    • ,
  • Pasquale Mansueto, M.D.

      Affiliations

    • Department of Internal Medicine, University of Palermo, Palermo, Italy
    • ,
  • GiovamBattista Rini, M.D.

      Affiliations

    • Department of Internal Medicine, University of Palermo, Palermo, Italy
    • ,
  • Michel Ferin, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Columbia University, New York, New York
    • ,
  • Rogerio A. Lobo, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Columbia University, New York, New York
    • Corresponding Author InformationReprint requests: Rogerio A. Lobo, M.D., Department of Obstetrics and Gynecology, Columbia University Medical Center, 622 West 168 Street, Rm. 16-69, New York, NY 10032 (FAX: 212-305-4326).

Received 17 November 2007 ,Revised 5 March 2008 ,Accepted 5 March 2008.

References 

  1. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Di Fede G, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab. 2007;92:2500–2505
  2. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–2556
  3. Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 2005;152:389–394
  4. Carmina E, Chu MC, Moran C, Tortoriello D, Vardana P, Tena G, et al. Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome. Fertil Steril. 2008;89:642–648
  5. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis alpha in normal-weight women with polycystic ovary syndrome. Metabolism. 1999;48:437–441
  6. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod. 2003;18:1790–1796
  7. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004;89:2563–2568
  8. Weyer C, Funahashi T, Tanaka S, Hotta K, Matuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–1935
  9. Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A, et al. Endothelial abnormalities in young women with PCOS: correlations with insulin resistance and decreased levels of serum adiponectin. Am J Med. 2006;119:356–361
  10. Kowalska I, Straczowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, Otziomek E, et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod. 2007;22:1824–1829
  11. Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril. 2007;88:401–405
  12. Weiping L, Qingfeng C, Shikun M, Xiurong L, Hua Q, Xiaoshu B, et al. Elevated serum RBP4 is associated with insulin resistance in women with polycystic ovary syndrome. Endocrine. 2006;30:283–288
  13. Tan BK, Chen J, Lehnert H, Kennedy R, Randeva HS. Raised serum, adipocyte and adipose tissue retinol binding protein 4 in overweight women with polycystic ovary syndrome: effects of gonadal and adrenal steroids. J Clin Endocrinol Metab. 2007;92:2764–2772
  14. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25
  15. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91:4237–4245
  16. Carmina E. The spectrum of androgen excess disorders. Fertil Steril. 2006;85:1582–1585
  17. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005;90:2545–2549
  18. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007;66:513–517
  19. Carmina E. Prevalence of idiopathic hirsutism. Eur J Endocrinol. 1998;139:421–423
  20. Carmina E, Orio F, Palomba S, Longo RA, Lombardi G, Lobo RA. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters. Fertil Steril. 2005;84:413–419
  21. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505–514
  22. Lobo RA, Kletzky OA, Kaptein EM, Goebelsmann U. Prolactin modulation of dehydroepiandrosterone sulfate secretion. Am J Obstet Gynecol. 1980;138:632–636
  23. Stanczyk FZ, Chang L, Carmina E, Putz Z, Lobo RA. Is 11 beta-hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate?. Am J Obstet Gyneol. 1991;165:1837–1842
  24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  25. Dominici R, Luraschi P, Franzini C. Measurement of C-reactive protein: two high sensitivity methods compared. J Clin Lab Anal. 2004;18:280–284
  26. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin-sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–2410
  27. Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2004;82:661–665
  28. Carmina E, Wong L, Chang L, Paulson RJ, Sauer MV, Stanczyk FZ, et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod. 1997;12:905–909

 E.C. has nothing to disclose. S.B. has nothing to disclose. P.M. has nothing to disclose. G.R. has nothing to disclose. M.F. has nothing to disclose. R.A.L. has nothing to disclose.

PII: S0015-0282(08)00582-7

doi: 10.1016/j.fertnstert.2008.03.007

Fertility and Sterility
Volume 91, Issue 4, Supplement , Pages 1332-1335 , April 2009

Article Tools

* Image Usage & Resolution